Top Markets
#1 Helium Helium +52.72%
#2 Seeker Seeker +50.59%
#3 Pons Pons +35.63%
#4 UnifAI Network UnifAI Network +31.30%
#5 Zylo Ecosystem Zylo Ecosystem +25.79%
#6 VVS Finance VVS Finance +24.87%
#7 TENDIES TENDIES +19.47%
#8 Bounce Bounce +17.09%
#9 Tensor Tensor +15.98%
#10 Songbird Songbird +15.53%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Genomma Lab Internacional, S.A.B. de C.V. Genomma Lab Internacional, S.A.B. de C.V.

Genomma Lab Internacional, S.A.B. de C.V.

LABB
Rank in Stocks #10943
Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies,... Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.
Share Price
$0.78199085
Last synced: 2026-08-28
Market Cap
$764.59M
Change (1 day)
-0.30%
Change (1 year)
-34.64%
Country
MX
Trade Genomma Lab Internacional, S.A.B. de C.V. (LABB)

Category

Healthcare
Revenue for Genomma Lab Internacional, S.A.B. de C.V. (LABB)
Revenue in Aug 2026 TTM: 0
According to Genomma Lab Internacional, S.A.B. de C.V. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Genomma Lab Internacional, S.A.B. de C.V. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN